Incidence of perioperative cardiac complications in patients with heart disease undergoing major oncosurgeries: A retrospective study

Sonali Opneia¹, Roopesh Sureshan¹, Satheeshan Balasubramanian², Jashma Nizam¹, Joona Prabhakaran¹, Namratha Diyakaran¹, Rahul Raveendran³, Rivas M⁴

- ¹Assistant Professor, Department of Anaesthesia, Malabar Cancer Centre, Thalassery, Kerala, India
- ² Director, Malabar Cancer Centre, Kerala, India
- ³ Senior Resident, Department of Onco-anaesthesiology, Malabar Cancer Centre, Kerala, India ⁴ Lecturer, Department of Biostatistics, Malabar Cancer Centre, Kerala, India

Background: Cardiac complications are the most important causes of morbidity | INTRODUCTION and mortality in the first 30 days after non cardiac surgery which result in prolonged length of stay, increased health care costs and poorer prognosis. Patients with coronary artery disease undergoing non-cardiac surgery are at an increased risk for peri-operative complications such as Myocardial Infarction(MI), cardiac failure, arrhythmias, cardiac arrest and increased morbidity and mortality.

Aim: To know the incidence of perioperative cardiac complications in patients with heart disease undergoing major oncosurgeries.

Settings and design: A retrospective analytic study was done in a tertiary care cancer centre in 70 heart disease patients who underwent oncosurgeries to know the incidence of perioperative cardiac complications within 7 days after surgery. Heart disease which were included in this study were congenital heart disease, ischemic heart disease, moderate and severe mitral stenosis, aortic stenosis, mitral regurgitation, aortic regurgitation, hypertrophic obstructive cardiomyopathy. Perioperative cardiac complications were noted in these patients intraoperatively and 7 days postoperatively.

Results: For the multivariate analysis, the value of alpha was adjusted and p-values at or below 0.2 were considered to be significant. In this study, history of previous surgery and moderate and high risk as diagnosed by cardiologist were found to significantly affect the incidence of intra/post-op complication in cardiac patients undergoing oncosurgeries.

Conclusion: Patients having any heart disease and having history of previous surgery or moderate and high risk diagnosed by cardiologist have more cardiac complications.

Key words: heart disease, complications, oncosurgeries

Address for correspondence:

Roopesh Sureshan, Assistant Professor, Department of Anaesthesia. Malabar Cancer Centre, Thalassery, Kerala PO-670 103, India, Email: roopesh14488@gmail.com

Word count: 4147 Tables: 09 Figures: 00 References: 22

Received: - 22 Sep, 2022, Manuscript No. OAR-22-75608

Editor assigned:- 24 Sep, 2022, PreQC No. OAR-22-75608 (PQ)

Reviewed:- 05 Oct 2022, QC No. OAR-22-75608 (Q)

Revised:- 10 Oct 2022, Manuscript No. OAR-22-75608 (R)

Published:-14 Oct 2022, Invoice No. OAR-22-75608

Cardiac complications are the most important causes of morbidity and mortality in the first 30 days after non-cardiac surgery which result in prolonged length of stay, increased health care costs and poorer prognosis and associate with perioperative factors, including advanced age, Coronary Artery Disease (CAD), renal insufficiency, diabetes, congestive Heart Failure (HF), types of surgery and other conditions [1-4].

Patients with coronary artery disease undergoing non-cardiac surgery are at an increased risk for peri-operative complications such as myocardial ischemia, MI, cardiac failure, arrhythmias, cardiac arrest and increased morbidity and mortality. These complications are much higher in patients with recent MI or unstable angina who require urgent or emergency cardiac surgery [1,5].

MATERIAL AND METHODS

This retrospective study was conducted after obtaining clearance from Institutional review board(1616/IRB-SRC/13/ MCC/08-01-2022/1). It was also registered in Clinical registry trial(CTRI/2022/01/039773). The primary objective of this retrospective study was to estimate the incidence and nature of cardiac complications in patients with heart disease intraoperatively and within 7 days postoperatively undergoing major oncosurgeries. Secondary objective was to assess the risk factors associated with perioperative cardiac complications and to know the thirty-day mortality and 90 days' mortality in patients with known cardiac illness undergoing major resection surgeries.

This study was conducted in the department of oncoanaesthesiology, Malabar Cancer Centre. The data of patients who had any heart disease diagnosed by cardiologist and had undergone major oncosurgeries from 1st January 2021 to 31st December 2021 was retrieved from Medical Records Department.

Inclusion criteria was age 25 years-85 years, ASA I and ASA II patients and those undergoing major oncosurgeries. Patients undergoing emergency surgery, American Society of Anesthesiologists (ASA) classification IV, V or VI and those who underwent two operations or more during the same hospitalization were excluded from this study.

Patients having any heart disease were studied for intraoperative

days of surgery.

CAD was diagnosed if any of the following conditions were met: CAD confirmed by coronary angiography, history of Myocardial Infarction (MI), history of coronary revascularization, positive myocardial perfusion scintigraphy, positive exercise stress test, or typical symptoms of angina pectoris with simultaneous signs of myocardial ischemia on the electrocardiograph.

Heart disease which were included in this study: Congenital heart disease, Ischemic heart disease, moderate and severe mitral stenosis, moderate and severe aortic stenosis, moderate and severe mitral regurgitation, moderate and severe aortic regurgitation, hypertrophic obstructive cardiomyopathy.

Perioperative Cardiac Complications (PCCs) were defined as: 70 patients were diagnosed with heart disease in 2021. Out of ACS included ST-Elevation Myocardial Infarction (STEMI) and these 70 patients, 62 patients underwent major oncosurgeries in NSTE-ACS was further subdivided into non-ST-elevation MI these 62 patients. and unstable angina according to the cardiac biomarkers.

Diagnosis of MI required a cTnl rise above the 99th percentile, accompanied by chest pain, ST-segment changes or new-onset left bundle branch block, ventricular wall motion abnormalities, or angiography confirmation. HF was diagnosed mainly by active clinical symptoms of dyspnea, orthopnea, peripheral edema, jugular venous distention, rales, third heart sound, or chest X-ray with pulmonary vascular redistribution or pulmonary oedema. New-onset severe arrhythmia was defined as ECG changes needing to be treated with drug or electrical conversion, including malignant ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation), atrial flutter or Atrial Fibrillation (AF), atrioventricular block (second-degree type II or third-degree), or frequent ventricular premature contractions.

Cardiac arrest was defined as the loss of circulation prompting resuscitation requiring chest compressions, defibrillation, or both.

Tab. 1. Table representin parameters, n=62

cardiac complications and postoperative complications within 7 or physical examination findings. Patients records were collected and analyzed for intraoperative and postoperative complications.

STATISTICS

Categorical variables were presented as numbers (%), and continuous variables was presented as the mean ± Standard Deviation (SD) or median and Inter-Quartile Range (IQR), depending on the distribution. A chi-square analysis was used between groups with and without PCCs to select possible risk factors of PCCs. SPSS software (IBM corporation) version 21 was used.

RESULTS

Non-ST-Elevation Acute Coronary Syndrome (NSTE-ACS). Malabar cancer Centre. Table 1 shows the demographic data of

17 patients developed complications, out of which 6 patients developed intraoperative complications and 11 patients developed postoperative complications.

Table 2 shows the intraoperative complications in these 6 patients.

Table 3 shows the postoperative complications in 17 patients.

Table 4 shows the comparison of patient parameters as per incidence of complications.

From the various factors, history of previous surgery was found to be statistically significant. This means that those patients who had previous surgery were at more risk for developing cardiac complications.

Table 5 shows the comparison of patient parameters as per incidence of intra-op complications.

ng various patient	C	haracteristic	N=621
		Median, (IQR)	65.00, (58.00, 70.00)
	Age	Range	38.00, 77.00
		Mean ± SD	63.24 ± 9.35
		F	29 (46.77%)
		М	33 (53.23%)
	C	IHD	52 (83.87%)
	Sex	Hypertension	37 (59.68%)
		Diabetes	27 (43.55%)
		Stroke	2 (3.23%)
		Median, (IQR)	58.00, (52.25, 65.00)
	Weight (kg)	Range	35.00, 98.00
		Mean ± SD	59.44 ± 10.93
		I	1 (1.61%)
	ASA Status	II	36 (58.06%)
		III	25 (40.32%)
		Characteristic	N=62
		Median, (IQR)	22.00, (16.00, 28.75)
	BUN	Range	8.00, 71.00
		Mean ± SD	23.84 ± 10.74
		Median, (IQR)	0.90, (0.80, 1.00)
	Creatinine	Range	0.40, 8.00
		Mean ± SD	1.02 ± 0.95

S. Opneja, et al. - Incidence of perioperative cardiac complications in patients with heart disease undergoing major oncosurgeries: A retrospective study

	Median, (IQR)	136.00, (133.00, 139.00)
Serum Sodium	Range	126.00, 144.00
	Mean ± SD	135.94 ± 3.87
	Median, (IQR)	4.40, (4.00, 4.60)
Serum Potassium	Range	3.40, 5.20
	Mean ± SD	4.32 ± 0.45
	Median, (IQR)	120.50, (97.25, 148.75)
Random Blood Sugar	Range	66.00, 357.00
	Mean ± SD	136.15 ± 55.31
	Median, (IQR)	1.00, (1.00, 1.00)
INR	Range	1.00, 1.27
	Mean ± SD	1.01 ± 0.04
	Median, (IQR)	1.76, (0.97, 2.53)
TSH	Range	0.38, 9.96
	Mean ± SD	2.13 ± 1.76
	History of Surgery	19 (30.65%)
Chausatauistia	Incidence of complications	17 (27.42%)
Characteristic	Incidence of intra-op complications	6 (9.68%)
	Incidence of Post-op Complications	11 (17.74%)

Tab. 2. Intraoperative complications	Intraoperative complications	No. of patients
	Hypotension	1
	Bradycardia	2
	Hypertension	3
	Total	6

Tab. 3. Postoperative complications.	Postoperative complications	Number of patients
	Bleeding	2
	ECG changes, Trop I normal	1
	Saturation fall	1
	Hypotension	3
	ECG changes, Trop I elevated	1
	Hypertension	2
	Bradycardia	1
	Total	11

Tab. 4. Shows the comparison of patient	Charact	eristic	No, N=45 ¹	Yes, N=171	p-value ²
parameters as per incidence of complications		Median (IQR)	65.00, (58.00, 70.00)	65.00, (58.00, 69.00)	
	Age	Range	43.00, 77.00	38.00, 73.00	0.6
		Mean ± SD	63.62 ± 9.41	62.24 ± 9.42	
		F	21 (46.67%)	8 (47.06%)	
		М	24 (53.33%)	9 (52.94%)	>0.9
		IHD	38 (84.44%)	14 (82.35%)	>0.9
	Sex	Hypertension	25 (55.56%)	12 (70.59%)	0.3
		Diabetes	18 (40.00%)	9 (52.94%)	0.4
		Stroke	1 (2.22%)	1 (5.88%)	0.5
		Median, (IQR)	60.00, (53.00, 67.00)	57.00, (49.00, 63.00)	
	Weight (kg)	Range	39.00, 80.00	35.00, 98.00	0.3
		Mean ± SD	60.16 ± 9.74	57.53 ± 13.75	
		I	1 (2.22%)	0 (0.00%)	
	ASA Status	II	24 (53.33%)	12 (70.59%)	0.6
		III	20 (44.44%)	5 (29.41%)	
	History of	Surgery	17 (37.78%)	2 (11.76%)	0.047
		Median, (IQR)	12.10, (11.10, 13.80)	11.50, (9.80, 13.60)	
	Haemoglobin	Range	8.10, 17.60	8.20, 15.80	0.4
	-	Mean ± SD	12.31 ± 1.89	11.74 ± 2.17	
		Madian (IOD)	8,500.00, (6,700.00,	8,100.00, (6,300.00,	
	Total Lauraauta Court	Median, (IQR)	10,100.00)	10,500.00)	07
	Total Leucocyte Count	Range	4,000.00, 15,100.00	4,700.00, 25,200.00	0.7
		Mean ± SD	8,646.67 ± 2,561.04	9,088.24 ± 4,659.38	

		268,000.00,	243,000.00,		
	Median, (IQR)	(237,000.00,	(206,000.00,	0.072	
		339,000.00)	274,000.00)		
Platelet Count	Range	128,000.00, 501,000.00	178,000.00, 343,000.00		
_		281.888.89 ±	244.588.24 ±		
	Mean ± SD	87,464.60	51,592.22		
	Median, (IQR)	23.00, (19.00, 28.00)	21.00, (15.00, 29.00)		
BUN	Range	8.00, 71.00	13.00, 41.00	0.5	
	Mean ± SD	24.44 ± 11.51	22.24 ± 8.45		
	Median, (IQR)	0.90, (0.70, 1.00)	0.90, (0.80, 1.00)		
Creatinine	Range	0.50, 1.90	0.40, 8.00	0.7	
	Mean ± SD	0.94 ± 0.31	1.25 ± 1.75		
	Median, (IQR)	136.00, (134.00,	136.00, (133.00,		
Serum Sodium	weulan, (IQK)	138.00)	139.00)	0.6	
Serum Sodium	Range	126.00, 144.00	131.00, 144.00	0.6	
	Mean ± SD	135.71 ± 3.82	136.53 ± 4.06		
	Median, (IQR)	4.40, (4.00, 4.60)	4.50, (4.20, 4.70)		
Serum Potassium	Range	3.40, 5.20	4.00, 5.00	0.12	
	Mean ± SD	4.26 ± 0.48	4.48 ± 0.31		
	Median, (IQR)	119.00, (98.00, 149.00)	121.00, (97.00, 148.00)		
Random Blood Sugar	Range	70.00, 357.00	66.00, 194.00	0.8	
	Mean ± SD	139.60 ± 60.85	127.00 ± 36.89		
	Median, (IQR)	1.00, (1.00, 1.00)	1.00, (1.00, 1.02)		
INR	Range	1.00, 1.27	1.00, 1.13	0.4	
	Mean ± SD	1.01 ± 0.04	1.01 ± 0.03		
	Median, (IQR)	1.72, (0.97, 2.59)	2.02, (1.01, 2.30)		
TSH	Range	0.38, 9.96	0.50, 5.17	0.9	
	Mean ± SD	2.17 ± 1.89	2.02 ± 1.40		

ab. 5. The comparison of patient parameters	Chara	cteristic	No. N= 56 ¹	Yes. N=6 ¹	p-value ²	
s per incidence of intra-op complications.		Median (IQR)	65.00, (57.75, 70.00)	68.00, (60.25, 69.75)		
	Age	Range	38.00, 77.00	52.00, 72.00	0.7	
		Mean ± SD	63.09 ± 9.55	64.67 ± 7.89		
		F	26 (46.43%)	3 (50.00%)		
		М	30 (53.57%)	3 (50.00%)	>0.9	
		IHD	47 (83.93%)	5 (83.33%)	>0.9	
	Sex	Hypertension	32 (57.14%)	5 (83.33%)	0.4	
		Diabetes	25 (44.64%)	2 (33.33%)	0.7	
		Stroke	2 (3.57%)	0 (0.00%)	>0.9	
		Median, (IQR)	59.00, (52.75, 65.50)	56.00, (49.00, 63.00)	. 010	
	Weight (kg)	Range	39.00, 98.00	35.00, 66.00	0.4	
		Mean ± SD	60.00 ± 10.80	54.17 ± 11.70		
		I	1 (1.79%)	0 (0.00%)		
	ASA Status	II	31 (55.36%)	5 (83.33%)	0.4	
			24 (42.86%)	1 (16.67%)		
		Median, (IQR)	11.95, (10.90, 13.72)	12.35, (11.55, 13.38)		
	Hemoglobin	Range	8.10, 17.60	8.60, 14.40	0.8	
		Mean ± SD	12.16 ± 1.98	12.12 ± 2.03		
	Total Leucocyte	Median, (IQR)	8,500.00, (6,650.00, 10,425.00)	7,400.00, (6,450.00, 8,050.00)		
	Count	Range	4,000.00, 25,200.00	6,300.00, 9,300.00	0.3	
		Mean ± SD	8,907.14 ± 3,357.81	7,466.67 ± 1,182.65		
	Platelet Count	Median, (IQR)	265,000.00, (215,500.00, 303,750.00)	270,000.00, (237,750.00, 326,250.00)	>0.9	
		Range	128,000.00, 501,000.00	178,000.00, 343,000.00		
		Mean ± SD	271,607.14 ± 82,640.66	272,166.67 ± 64,396.95		
		Median, (IQR)	22.00, (16.00, 28.50)	22.00, (16.75, 27.25)		
	BUN	Range	8.00, 71.00	14.00, 30.00	0.8	
		Mean ± SD	24.04 ± 11.11	22.00 ± 6.72		

	Median, (IQR)	0.90, (0.78, 1.00)	0.90, (0.83, 0.90)		
Creatinine	Range	0.40, 8.00	0.60, 1.00	0.7	
	Mean ± SD	1.04 ± 0.99	0.85 ± 0.14		
	Median, (IQR)	136.00, (133.75, 139.00)	136.00, (132.25, 142.00)		
Serum Sodium	Range	126.00, 144.00	131.00, 144.00	0.7	
	Mean ± SD	135.82 ± 3.67	137.00 ± 5.76		
	Median, (IQR)	4.45, (4.00, 4.60)	4.30, (4.20, 4.55)		
Serum Potassium	Range	3.40, 5.20	4.00, 4.80	>0.9	
	Mean ± SD	4.32 ± 0.46	4.37 ± 0.29		
	Median, (IQR)	120.00, (97.00, 153.25)	125.50, (105.75, 140.00)		
Random Blood	Range	66.00, 357.00	89.00, 148.00	0.9	
Sugar	Mean ± SD	137.66 ± 57.61	122.00 ± 23.38		
	Median, (IQR)	1.00, (1.00, 1.00)	1.00, (1.00, 1.02)		
INR	Range	1.00, 1.27	1.00, 1.13	0.5	
	Mean ± SD	1.01 ± 0.04	1.03 ± 0.05		
	Median, (IQR)	1.76, (0.96, 2.52)	1.98, (1.17, 4.44)		
	Range	0.38, 9.96	0.77, 5.17	0.5	
	Mean ± SD	2.07 ± 1.74	2.68 ± 2.00		
TSH	History of Surgery	19 (33.93%)	0 (0.00%)	0.2	
		1n (%)		
		2Wilcoxon rank sum test	; Fisher's exact test		
	Median, (IQR)	4.45, (4.00, 4.60)	4.30, (4.20, 4.55)		
Serum Potassium	Range	3.40, 5.20	4.00, 4.80	>0.9	
	Mean ± SD	4.32 ± 0.46	4.37 ± 0.29		
	Median, (IQR)	120.00, (97.00, 153.25)	125.50, (105.75, 140.00)		
Random Blood	Range	66.00, 357.00	89.00, 148.00	0.9	
Sugar	Mean ± SD	137.66 ± 57.61	122.00 ± 23.38		
	Median, (IQR)	1.00, (1.00, 1.00)	1.00, (1.00, 1.02)		
INR	Range	1.00, 1.27	1.00, 1.13	0.5	
	Mean ± SD	1.01 ± 0.04	1.03 ± 0.05		
	Median, (IQR)	1.76, (0.96, 2.52)	1.98, (1.17, 4.44)		
	Range	0.38, 9.96	0.77, 5.17	0.5	
TSH	Mean ± SD	2.07 ± 1.74	2.68 ± 2.00		
	History of Surgery	19 (33.93%)	0 (0.00%)	0.2	
		1n (%)	· ·]		
	214/:100	on rank sum test; Fisher's	ovact tast		

S. Opneja, et al. - Incidence of perioperative cardiac complications in patients with heart disease undergoing major oncosurgeries: A retrospective study

incidence of post-op complications.

Table 7 shows the univariate regression analysis of various factors.

Table 8 shows the multivariate regression analysis of various factors.

For the multivariate analysis, the value of alpha was adjusted and substrate for cardiac complications after surgery [8-11]. p-values at or below 0.2 were considered to be significant.

In our analysis, history of previous surgery and moderate risk were found to significantly affect the incidence of intra/post-op complication in cardiac patients undergoing oncosurgeries.

The risk of complications in patients who have undergone previous surgery was 24% more than the patients who have not undergone any previous surgery.

Similarly, patients with moderate risk (as assessed by cardiologist) were 4.64 times more likely to develop complications as compared to patients with mild risk. (CI: 0.61, 46.4; p=0.2). Patients with high risk diagnosed by cardiologist were also 1.90 times more independent risk factors for perioperative cardiac complications. likely to develop complications (CI:0.42,9.16; p=0.12).

DISCUSSIONS

Goldman et al. reported that 500,000-900,000 Myocardial

Table 6 shows the comparison of patient parameters as per Infarctions (MIs) occur annually worldwide with subsequent mortality of 10%-25%. The number of people with coronary artery disease with or without intervention coming for noncardiac procedures has also increased [6,7].

> Large, prospective cohort studies have shown that several chronic cardiac conditions such as coronary artery disease provide a

> Examples of recent preoperative conditions that are independently associated with perioperative cardiac complications are high-risk coronary artery disease (i.e., myocardial infarction or Canadian Cardiovascular Society class (CCSC) III or IV angina within 6 months before surgery), stroke within 3 months before surgery, and coronary-artery stenting within 6 months before surgery [8,12-17].

> The incidence of perioperative cardiac complications in our study was 27.41%. Our study revealed history of previous surgery and moderate and high risk as diagnosed by cardiologist as

Table 9 shows the various surgeries studied in our study.

In this study we did not get any correlation between advancing age and incidence of perioperative cardiac complications but previous

Cha	aracteristic	No, N=51 ¹	Yes, N=11 ¹	p-value ²
	Median, (IQR)	65.00, (58.00, 70.00)	65.00, (56.00, 68.00)	
Age	Range	43.00, 77.00	38.00, 73.00	0.4
	Mean ± SD	63.75 ± 9.18	60.91 ± 10.26	
	F	24 (47.06%)	5 (45.45%)	>0.9
	Μ	27 (52.94%)	6 (54.55%)	>0.9
Cov.	IHD	43 (84.31%)	9 (81.82%)	>0.9
Sex	Hypertension	30 (58.82%)	7 (63.64%)	>0.9
	Diabetes	20 (39.22%)	7 (63.64%)	0.2
	Stroke	1 (1.96%)	1 (9.09%)	0.3
	Median, (IQR)	60.00, (52.50, 65.50)	57.00, (52.00, 61.50)	
Weight (kg)	Range	35.00, 80.00	41.00, 98.00	0.6
	Mean ± SD	59.45 ± 10.05	59.36 ± 14.95	
	I	1 (1.96%)	0 (0.00%)	
ASA Status	II	29 (56.86%)	7 (63.64%)	>0.9
		21 (41.18%)	4 (36.36%)	
	Median, (IQR)	12.10, (11.15, 13.70)	11.20, (9.75, 12.85)	
Hemoglobin	Range	8.10, 17.60	8.20, 15.80	0.2
	Mean ± SD	12.29 ± 1.89	11.53 ± 2.30	1
Total Leucocyte	Median, (IQR)	8,100.00, (6,700.00, 9,550.00)	8,900.00, (6,150.00, 10,950.00)	
Count	Range	4,000.00, 15,100.00	4,700.00, 25,200.00	0.6
	Mean ± SD	8,507.84 ± 2,461.53	9,972.73 ± 5,621.23	
	Median, (IQR)	268,000.00, (236,500.00, 338,000.00)	236,000.00, (198,000.00, 263,000.00)	
Platelet Count	Range	128,000.00, 501,000.00	179,000.00, 281,000.00	0.035
	Mean ± SD	280,745.10 ± 84,597.60	229,545.45 ± 38,471.71	
	Median, (IQR)	22.00, (17.50, 28.50)	19.00, (15.00, 29.00)	
BUN	Range	8.00, 71.00	13.00, 41.00	0.5
	Mean ± SD	24.16 ± 11.04	22.36 ± 9.57	
	Median, (IQR)	0.90, (0.75, 1.00)	0.90, (0.80, 1.00)	
Creatinine	Range	0.50, 1.90	0.40, 8.00	>0.9
	Mean ± SD	0.93 ± 0.30	1.46 ± 2.18	
	Median, (IQR)	136.00, (133.00, 139.00)	136.00, (134.00, 139.00)	
Serum Sodium	Range	126.00, 144.00	131.00, 140.00	0.7
	Mean ± SD	135.86 ± 4.04	136.27 ± 3.10	
	Median, (IQR)	4.40, (4.00, 4.60)	4.50, (4.35, 4.75)	
	Range	3.40, 5.20	4.00, 5.00	0.082
	Mean ± SD	4.27 ± 0.46	4.55 ± 0.32	
Random Blood	Median, (IQR)	120.00, (98.50, 147.50)	121.00, (94.50, 168.00)	
Sugar	Range	70.00, 357.00	66.00, 194.00	>0.9
	Mean ± SD	137.53 ± 57.84	129.73 ± 43.37	
	Median, (IQR)	1.00, (1.00, 1.00)	1.00, (1.00, 1.01)	
INR	Range	1.00, 1.27	1.00, 1.04	0.7
	Mean ± SD	1.01 ± 0.04	1.01 ± 0.01	
	Median, (IQR)	1.72, (0.97, 2.66)	2.02, (0.92, 2.17)	
				- 0 5
	Range	0.38, 9.96	0.50, 3.09	0.5
тѕн —	Range Mean ± SD	0.38, 9.96 2.23 ± 1.89	0.50, 3.09 1.65 ± 0.84	0.5
	Age Sex Weight (kg) ASA Status Hemoglobin Total Leucocyte Count Platelet Count BUN BUN Serum Sodium Serum Sodium Serum Blood Sugar	AgeRangeMean ± SDMean ± SDMean ± SDMHDHypertensionDiabetesStrokeMedian, (IQR)Weight (kg)RangeMedian, (IQR)Median, (IQR)HemoglobinRangeMedian, (IQR)HemoglobinRangeMedian, (IQR)Total LeucocyteCountMedian, (IQR)Platelet CountRangeMedian, (IQR)Platelet CountRangeMedian, (IQR)Platelet CountRangeMedian, (IQR)CreatinineRangeMedian, (IQR)Serum SodiumRangeMedian, (IQR)Serum SodiumRangeMedian, (IQR)RangeMedian, (IQR)RangeMedi	Age Median, (IQR) 65.00, (58.00, 70.00) Range 43.00, 77.00 Mean ± SD 63.75 ± 9.18 F 24 (47.06%) M 27 (52.94%) IHD 43 (84.31%) Hypertension 30 (58.82%) Diabetes 20 (39.22%) Stroke 1 (1.96%) Weight (kg) Range 35.00, 80.00 Median, (IQR) 60.00, (52.50, 65.50) Weight (kg) Range 35.00, 80.00 Median, I(QR) 11 1(1.96%) ASA Status II 29 (56.86%) III 21 (41.18%) 12.10, (11.15, 13.70) Median, (IQR) 12.10, (11.15, 13.70) Median, (IQR) 8,100.00, (6,700.00, 9,550.00) Count Range 4,000.00, 15,100.00 Median, (IQR) 8,507.84 ± 2,461.53 Count Median, (IQR) 268,000.00, 138,000.00 Median, (IQR) 226,500.00, 338,000.00 338,000.00 Platelet Count Range 12.80,000, 50, 10.00 Median, (IQR) <td< td=""><td>Median, (IQR) 65.00, (58.00, 70.00) 65.00, (56.00, 68.00) Age Range 43.00, 77.00 38.00, 73.00 Mean ± SD 63.75 ± 9.18 60.91 ± 10.26 M 27 (52.94%) 6 (54.55%) IHD 43 (84.31%) 9 (81.82%) Hypertension 30 (58.82%) 7 (63.64%) Diabetes 20 (39.22%) 7 (63.64%) Weight (kg) Range 35.00, 80.00 41.09.98.00 Median, (IQR) 60.00, (52.50, 65.50) 57.00, (52.00, 61.50) Median, (IQR) 60.00, (52.50, 65.50) 59.36 ± 14.95 Median, (IQR) 11.196%) 0 (0.00%) ASA Status II 21 (56.86%) 7 (63.64%) III 21 (21.01, (11.5, 13.70) 11.20, (9.75, 12.85) Median, (IQR) 12.10, (11.15, 13.70) 11.20, (9.75, 12.85) Median, (IQR) 8,100.00, (6,700.00) 8,900.00, (6,150.00, 0) Count Range 8,007.00, 28,000.00, 28,000.00, 26,300.00, 28,000.00, 28,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,0</td></td<>	Median, (IQR) 65.00, (58.00, 70.00) 65.00, (56.00, 68.00) Age Range 43.00, 77.00 38.00, 73.00 Mean ± SD 63.75 ± 9.18 60.91 ± 10.26 M 27 (52.94%) 6 (54.55%) IHD 43 (84.31%) 9 (81.82%) Hypertension 30 (58.82%) 7 (63.64%) Diabetes 20 (39.22%) 7 (63.64%) Weight (kg) Range 35.00, 80.00 41.09.98.00 Median, (IQR) 60.00, (52.50, 65.50) 57.00, (52.00, 61.50) Median, (IQR) 60.00, (52.50, 65.50) 59.36 ± 14.95 Median, (IQR) 11.196%) 0 (0.00%) ASA Status II 21 (56.86%) 7 (63.64%) III 21 (21.01, (11.5, 13.70) 11.20, (9.75, 12.85) Median, (IQR) 12.10, (11.15, 13.70) 11.20, (9.75, 12.85) Median, (IQR) 8,100.00, (6,700.00) 8,900.00, (6,150.00, 0) Count Range 8,007.00, 28,000.00, 28,000.00, 26,300.00, 28,000.00, 28,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,000.00, 283,0

2Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

S. Opneja, et al. - Incidence of perioperative cardiac complications in patients with heart disease undergoing major oncosurgeries: A retrospective study

Tab. 7. Shows the univariate regression	Charact	eristic	N	OR1	95% Cl ¹	p-value
analysis of various factors		Age	62	1	0.93, 1.05	0.6
		F	62	-	-	
	Sex	М	62	1	0.32, 3.06	>0.9
		No	62	_	_	
	IHD	Yes	62	0.9	0.21, 4.41	0.8
		No	62	_	_	
	History of Surgery	Yes	62	0.2	0.03, 0.91	0.062
	LV changes	Absent	62	_	_	
		Present	62	1	0.30, 2.96	>0.9
	Stenosis	Absent	62	_	_	
		Present	62	0		>0.9
	ECG changes	Absent	62	_	_	
		Present	62	0.7	0.23, 2.19	0.6
		Absent	62	_	_	
	Dogurgitation	Present	62	0		>0.9
	Regurgitation	1OR=Odds Ratio, CI=Confidence Interval	62			

Tab. 8. Multivariate regression analysis of	Characte	ristic	OR	95%CI	p-value
various factors.	Age		0.97	0.89, 1.05	0.5
	Co	F	_	_	
	Sex	М	0.74	0.16, 3.21	0.7
	IHD	No	_	_	
	IHD	Yes	0.33	0.03, 2.72	0.3
	listen of Conserve	No	_	—	
	History of Surgery	Yes	0.23	0.03, 1.23	0.11
	1) / shares	Absent	_	—	
	LV changes	Present	0.84	0.20, 3.60	0.8
	Stenosis	Absent	_	_	
	Stenosis	Present	0		>0.9
	FCC shares	Absent	_	—	
	ECG changes	Present	0.53	0.11, 2.33	0.4
		Absent	_	—	
	Regurgitation	Present	0		>0.9
		MILD RISK	_	_	
		MODERATE RISK	4.64	0.61, 46.4	0.2
	Risk of Surgery	STANDARD RISK	0		>0.9
	NISK OF SUISELY	HIGH RISK	1.9	0.42, 9.16	0.12
		1 OR=Odds Ratio,			
		CI=Confidence Interval			

Tab. 9. The various surgeries studied in our	Type of surgery	No. of cases
study.	Endometrium and ovary	10
	Head and neck	25
	Breast	14
	Bladder and RCC	3
	Colon and Rectum	9
	Pheochromocytoma	1
	Stomach	8
	Total	70

postoperative complications. In a prospective large-scale study, diabetes mellitus, and renal dysfunction and other risk factors in CAD history and age \geq 75 were both independent predictors the general population were not independent predictors of PCCs of MI in non-cardiac surgery, with 10.3% and 23.5% population in this study [19,20]. attribute risk, respectively [18].

cardiologist was also associated with increased incidence of intraoperative and postoperative cardiac complications.

studies have shown advancing age as independent risk factor for Several related chronic conditions like cerebrovascular disease,

The main limitation of our study is the relatively small number of We also found that moderate and high risk as diagnosed by patients. As a retrospective study, some preoperative information was unavailable including cTnl levels, and we could not comment on the role of preoperative medical management in modifying the risk of PCCs [21].

of PCCs, which might lead to a missed diagnosis of silent MI. increased in patients who have history of previous surgery and those Moreover, asymptomatic silent troponin level elevation alone is diagnosed as moderate and high risk for surgery by cardiologist. strongly associated with mortality [22].

More prospective studies should be designed to evaluate the risk factors and prophylactic cardiac interventions, and make comprehensive predictive stratification models that allow for better preoperative optimization as to minimize PCCs.

CONCLUSION

Postoperative troponin was tested only if clinical or ECG evidence in patients having history of heart disease. This risk is further So, special precautions should be taken in these patients to avoid complications both intraoperatively and postoperatively.

FINANCIAL SUPPORT AND SPONSORSHIP

Nil

CONFLICTS OF INTEREST

The incidence of perioperative cardiac complications is high There are no conflicts of interest

REFERENCES

- Kristensen SD, Knuuti J, Saraste A, Hans Erik Bøtker, Stefan De Hert et al. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anesthesiology (ESA). Eur Heart J 2014; 35:2383-2431.
- Sellers D, Srinivas C, Djaiani G. Cardiovascular complications after noncardiac surgery. Anaesthesia. 2018;73:34-42.
- Sellers D, Srinivas C, Djaiani G. Cardiovascular complications after noncardiac surgery. Anaesthesia. 2018;73:34-42.
- Elsiwy Y, Jovanovic I, Doma K, Hazratwala K, Letson H. Risk factors associated with cardiac complication after total joint arthroplasty of the hip and knee: a systematic review. J. Orthop. Surg. Res.2019;14:1-2.
- Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;64:e77-137.
- Kozak LJ, Hall MJ, Owings M. National Hospital Discharge Survey; 2000 annual summary, with detailed diagnosis and procedure data.Kaul TK, Tayal G. Anaesthetic considerations in cardiac patients undergoing non cardiac surgery. Indian J Anaesth.2007;51:280-286.
- Kaul TK, Tayal G. Anaesthetic considerations in cardiac patients undergoing non cardiac surgery. Indian J Anaesth.2007;51:280-286.
- Botto F, Alonso-Coello P, Chan MT, et al. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology 2014; 120:564-78
- Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999; 100:1043-1049.
- Sabaté S, Mases A, Guilera N, et al. Incidence and predictors of major perioperative adverse cardiac and cerebrovascular events in non-cardiac surgery. Br J Anaesth.2011;107:879-890.
- Gupta PK, Gupta H, Sundaram A, Kaushik M, Fang X, et al. Development and validation of a risk calculator for prediction of cardiac risk after surgery. Circulation. 2011;124:381-387.

- 12. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977;297:845-850
- 13. Kumar R, McKinney WP, Raj G, et al. Adverse cardiac events after surgery: assessing risk in a veteran population. J Gen Intern Med.2001;16:507-518
- 14. Detsky AS, Abrams HB, McLaughlin JR, et al. Predicting cardiac complications in patients undergoing non-cardiac surgery. J Gen Intern Med. 1986;1:2
- Jørgensen ME, Torp-Pedersen C, Gislason GH, et al. Time elapsed after ischemic stroke and risk of adverse cardiovascular events and mortality following elective noncardiac surgery. JAMA.2014; 312:269-277.
- Hawn MT, Graham LA, Richman JS, Itani KM, Henderson WG, et al. Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. JAMA. 2013;310:1462-1472.
- 17. Wijeysundera DN, Wijeysundera HC, Yun L, Wąsowicz M, Beattie WS, et al. Risk of elective major noncardiac surgery after coronary stent insertion: a populationbased study. Circulation. 2012;126:1355-1462.
- Devereaux PJ, Sessler DJ, Leslie K, Kurz A, Mrkobrada M, et al. Clonidine in patients undergoing noncardiac surgery. N Engl J Med. 2014;370:1504-1513.
- Longrois D, Hoeft A, De Hert S. 2014 European Society of Cardiology/European Society of Anaesthesiology guidelines on non-cardiac surgery: cardiovascular assessment and managementA short explanatory statement from the European Society of Anaesthesiology members who participated in the European Task Force. Eur J Anaesthesiol J EJA. 2014; 31:513-516.
- 20. Wijeysundera DN, Duncan D, Nkonde-Price C, Virani SS, Washam JB, et al. Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;130:2246-2264.
- 21. Zhao BC, Liu WF, Deng QW, Zhuang PP, Liu J, et al. Meta-analysis of preoperative high-sensitivity cardiac troponin measurement in non-cardiac surgical patients at risk of cardiovascular complications. J Br Surg. 2020;107:81-90.
- Sessler DI, Devereaux PJ. Perioperative troponin screening. Anesth Analg. 2016;123:359-360.